{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:18:03Z","timestamp":1794406683688,"version":"4.9.0"},"reference-count":161,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health Research, Diabetes UK"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Avacta Life Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbidity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced thrombotic environment, contributes to the high vascular risk in individuals with DM. This prothrombotic milieu is due to increased platelet activity together with impaired fibrinolysis secondary to quantitative and qualitative changes in coagulation factors. However, management strategies to reduce thrombosis risk remain largely similar in individuals with and without DM. The current review covers the latest in the field of antithrombotic management in DM. The role of primary vascular prevention is discussed together with options for secondary prevention following an ischaemic event in different clinical scenarios including coronary, cerebrovascular, and peripheral artery diseases. Antiplatelet therapy combinations as well as combination of antiplatelet and anticoagulant agents are examined in both the acute phase and long term, including management of individuals with sinus rhythm and those with atrial fibrillation. The difficulties in tailoring therapy according to the variable atherothrombotic risk in different individuals are emphasized, in addition to the varying risk within an individual secondary to DM duration, presence of complications and predisposition to bleeding events. This review provides the reader with an up-to-date guide for antithrombotic management of individuals with DM and highlights gaps in knowledge that represent areas for future research, aiming to improve clinical outcome in this high-risk population.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehab128","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T20:37:28Z","timestamp":1614112648000},"page":"2235-2259","source":"Crossref","is-referenced-by-count":62,"title":["Antithrombotic therapy in diabetes: which, when, and for how long?"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-3725","authenticated-orcid":false,"given":"Ramzi A","family":"Ajjan","sequence":"first","affiliation":[{"name":"The LIGHT Laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds LS2 7JT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-4450","authenticated-orcid":false,"given":"Noppadol","family":"Kietsiriroje","sequence":"additional","affiliation":[{"name":"The LIGHT Laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds LS2 7JT, UK"},{"name":"Endocrinology and Metabolism Unit, Internal Medicine Department, Faculty of Medicine, Prince of Songkla University , Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-2459","authenticated-orcid":false,"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[{"name":"Cardiovascular Program ICCC, Research Institute Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , Sant Antoni M. Claret 167, 08025 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III , Sant Antoni M. Claret 167, 08025 Barcelona, Spain"},{"name":"Cardiovascular Research Chair, Universidad Aut\u00f3noma Barcelona (UAB) , Sant Antoni M. Claret 167, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Vilahur","sequence":"additional","affiliation":[{"name":"Cardiovascular Program ICCC, Research Institute Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , Sant Antoni M. Claret 167, 08025 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III , Sant Antoni M. Claret 167, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1451","authenticated-orcid":false,"given":"Diana A","family":"Gorog","sequence":"additional","affiliation":[{"name":"University of Hertfordshire , College Lane Campus Hatfield, Hertfordshire AL10 9AB, UK"},{"name":"National Heart and Lung Institute, Guy Scadding Building, Dovehouse St , London SW3 6LY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine \u2013 Jacksonville, 655 West, 8th Street , Jacksonville, FL 32209, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1293-5618","authenticated-orcid":false,"given":"David A","family":"Russell","sequence":"additional","affiliation":[{"name":"The LIGHT Laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds LS2 7JT, UK"},{"name":"Leeds Vascular Institute, Leeds General Infirmary, Great George Street , Leeds LS1 3EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Catholic University School of Medicine , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield , Beech Hill Road, Sheffield S10 2RX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"2022102603082494300_ehab128-B1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","author":"Di Angelantonio","year":"2015","journal-title":"JAMA"},{"key":"2022102603082494300_ehab128-B2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B3","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/eurheartj\/ehy677","article-title":"Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable","volume":"40","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B4","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/ijms19102968","article-title":"The main determinants of diabetes mellitus vascular complications: endothelial dysfunction and platelet hyperaggregation","volume":"19","author":"Carrizzo","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2022102603082494300_ehab128-B5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.21037\/cdt.2018.05.09","article-title":"Diabetes and antiplatelet therapy: from bench to bedside","volume":"8","author":"Rivas Rios","year":"2018","journal-title":"Cardiovasc Diagn Ther"},{"key":"2022102603082494300_ehab128-B6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","article-title":"Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk","volume":"16","author":"Kearney","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2022102603082494300_ehab128-B7","doi-asserted-by":"crossref","first-page":"e4495","DOI":"10.1097\/MD.0000000000004495","article-title":"Venous thromboembolism has the same risk factors as atherosclerosis: a PRISMA-compliant systemic review and meta-analysis","volume":"95","author":"Mi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2022102603082494300_ehab128-B8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.tem.2019.05.003","article-title":"Platelets as potent signaling entities in type 2 diabetes mellitus","volume":"30","author":"Pretorius","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"2022102603082494300_ehab128-B9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12933-016-0373-x","article-title":"Flow cytometric analysis of platelets type 2 diabetes mellitus reveals \u2018angry\u2019 platelets","volume":"15","author":"Soma","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"2022102603082494300_ehab128-B10","doi-asserted-by":"crossref","first-page":"781857","DOI":"10.1155\/2014\/781857","article-title":"Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis","volume":"2014","author":"Ghoshal","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"2022102603082494300_ehab128-B11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3389\/fphar.2019.01244","article-title":"Measurement of thromboxane biosynthesis in health and disease","volume":"10","author":"Patrono","year":"2019","journal-title":"Front Pharmacol"},{"key":"2022102603082494300_ehab128-B12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0609.1998.tb01095.x","article-title":"Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus","volume":"61","author":"Watala","year":"2009","journal-title":"Eur J Haematol"},{"key":"2022102603082494300_ehab128-B13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prostaglandins.2015.05.002","article-title":"Platelets and diabetes mellitus","volume":"120","author":"Santilli","year":"2015","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2022102603082494300_ehab128-B14","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1161\/01.CIR.101.24.2833","article-title":"Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo","volume":"101","author":"Audoly","year":"2000","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B15","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1538-7836.2009.03637.x","article-title":"Insulin\/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function","volume":"7","author":"Hunter","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2022102603082494300_ehab128-B16","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1042\/CS20160391","article-title":"Thrombosis in diabetes: a shear flow effect?","volume":"131","author":"Westein","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"2022102603082494300_ehab128-B17","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2337\/diacare.24.8.1476","article-title":"Platelet dysfunction in type 2 diabetes","volume":"24","author":"Vinik","year":"2001","journal-title":"Diabetes Care"},{"key":"2022102603082494300_ehab128-B18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1160\/TH16-04-0322","article-title":"Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus","volume":"117","author":"Fejes","year":"2017","journal-title":"Thromb Haemost"},{"key":"2022102603082494300_ehab128-B19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12933-019-0918-x","article-title":"Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review","volume":"18","author":"Pordzik","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022102603082494300_ehab128-B20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1055\/s-0038-1648983","article-title":"Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo","volume":"72","author":"Gawaz","year":"1994","journal-title":"Thromb Haemost"},{"key":"2022102603082494300_ehab128-B21","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1161\/ATVBAHA.112.255281","article-title":"Platelets derived from the bone marrow of diabetic animals show dysregulated endoplasmic reticulum stress proteins that contribute to increased thrombosis","volume":"32","author":"Hern\u00e1ndez Vera","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102603082494300_ehab128-B22","doi-asserted-by":"crossref","first-page":"C328","DOI":"10.1152\/ajpcell.00560.2006","article-title":"Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A\/2C receptors","volume":"293","author":"Wang","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"2022102603082494300_ehab128-B23","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2022102603082494300_ehab128-B24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","article-title":"New insights into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2022102603082494300_ehab128-B25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1479164110383994","article-title":"Platelet abnormalities in diabetes mellitus","volume":"7","author":"Ferreiro","year":"2010","journal-title":"Diab Vasc Dis Res"},{"key":"2022102603082494300_ehab128-B26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1479164110383723","article-title":"Coagulation and fibrinolysis in diabetes","volume":"7","author":"Alzahrani","year":"2010","journal-title":"Diab Vasc Dis Res"},{"key":"2022102603082494300_ehab128-B27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jdiacomp.2014.01.006","article-title":"High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications","volume":"28","author":"Kim","year":"2014","journal-title":"J Diabetes Complications"},{"key":"2022102603082494300_ehab128-B28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2013-04-494641","article-title":"Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity","volume":"122","author":"Ajjan","year":"2013","journal-title":"Blood"},{"key":"2022102603082494300_ehab128-B29","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.1073\/pnas.97.22.12222","article-title":"Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation","volume":"97","author":"Du","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022102603082494300_ehab128-B30","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B31","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/eurheartj\/ehq021","article-title":"Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis","volume":"31","author":"Ducrocq","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B32","doi-asserted-by":"crossref","first-page":"e008354","DOI":"10.1161\/JAHA.117.008354","article-title":"Association of diabetic status and glycemic control with ischemic and bleeding outcomes in patients with stable coronary artery disease: the 5-Year CORONOR Registry","volume":"7","author":"Lemesle","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022102603082494300_ehab128-B33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5853\/jos.2020.01886","article-title":"Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences","volume":"22","author":"Goel","year":"2020","journal-title":"J Stroke"},{"key":"2022102603082494300_ehab128-B34","doi-asserted-by":"crossref","first-page":"e013894","DOI":"10.1136\/bmjopen-2016-013894","article-title":"Risk of disseminated intravascular coagulation in patients with type 2 diabetes mellitus: retrospective cohort study","volume":"7","author":"Nogami","year":"2017","journal-title":"BMJ Open"},{"key":"2022102603082494300_ehab128-B35","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.116.023164","article-title":"Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus","volume":"134","author":"Capodanno","year":"2016","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"key":"2022102603082494300_ehab128-B38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2022102603082494300_ehab128-B39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","article-title":"Platelet thrombin receptor antagonism and atherothrombosis","volume":"31","author":"Angiolillo","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40256-013-0022-7","article-title":"Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents","volume":"13","author":"Angiolillo","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"2022102603082494300_ehab128-B42","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B43","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"2022102603082494300_ehab128-B44","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"2022102603082494300_ehab128-B45","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B46","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B47","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B48","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B49","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2016.02.056","article-title":"Validation of BARC bleeding criteria in patients with acute coronary syndromes: the TRACER trial","volume":"67","author":"Vranckx","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12933-019-0875-4","article-title":"Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials","volume":"18","author":"Seidu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022102603082494300_ehab128-B51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B52","first-page":"S103","article-title":"10. Cardiovascular Disease and Risk Management: standards of Medical Care in Diabetes-2019","volume":"42(Suppl 1","year":"2019","journal-title":"Diabetes Care"},{"key":"2022102603082494300_ehab128-B53","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"2022102603082494300_ehab128-B54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cjca.2010.12.033","article-title":"The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary","volume":"27","author":"Bell","year":"2011","journal-title":"Can J Cardiol"},{"key":"2022102603082494300_ehab128-B55","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12933-015-0232-1","article-title":"Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study","volume":"14","author":"Alexopoulos","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2022102603082494300_ehab128-B58","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1160\/TH16-09-0703","article-title":"Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status","volume":"117","author":"Thomas","year":"2017","journal-title":"Thromb Haemost"},{"key":"2022102603082494300_ehab128-B59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102603082494300_ehab128-B60","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"Spectre","year":"2011","journal-title":"Thromb Haemost"},{"key":"2022102603082494300_ehab128-B61","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11886-016-0749-2","article-title":"The ADAPTABLE trial and aspirin dosing in secondary prevention for patients with coronary artery disease","volume":"18","author":"Johnston","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"2022102603082494300_ehab128-B63","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11239-019-01933-7","article-title":"Pharmacokinetic\/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study","volume":"48","author":"Angiolillo","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2022102603082494300_ehab128-B64","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus","volume":"69","author":"Bhatt","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B65","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B66","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B67","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B68","doi-asserted-by":"crossref","first-page":"e011139","DOI":"10.1161\/JAHA.118.011139","article-title":"Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial","volume":"8","author":"Franchi","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022102603082494300_ehab128-B69","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Schupke","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B70","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jcin.2020.07.032","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetes mellitus","volume":"13","author":"Ndrepepa","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102603082494300_ehab128-B71","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B72","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.4244\/EIJ-D-18-01077","article-title":"Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial","volume":"15","author":"Hein","year":"2019","journal-title":"EuroIntervention"},{"key":"2022102603082494300_ehab128-B73","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B74","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B75","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.01.002","article-title":"Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study","volume":"295","author":"Chichareon","year":"2020","journal-title":"Atherosclerosis"},{"key":"2022102603082494300_ehab128-B77","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12933-020-01153-x","article-title":"Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial","volume":"19","author":"Gao","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2022102603082494300_ehab128-B78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.amjcard.2020.04.027","article-title":"Meta-analysis of dual antiplatelet therapy versus monotherapy with P2Y12 inhibitors in patients after percutaneous coronary intervention","volume":"127","author":"Malik","year":"2020","journal-title":"Am J Cardiol"},{"key":"2022102603082494300_ehab128-B79","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2020.06.085","article-title":"Trial design principles for patients at high bleeding risk undergoing PCI: JACC Scientific Expert Panel","volume":"76","author":"Capodanno","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B80","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/hc4801.100029","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes","volume":"104","author":"Roffi","year":"2001","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B81","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"2022102603082494300_ehab128-B82","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B83","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/09537104.2019.1665642","article-title":"Use of glycoprotein IIb\/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction","volume":"31","author":"Zwart","year":"2020","journal-title":"Platelets"},{"key":"2022102603082494300_ehab128-B84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B85","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B86","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B87","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"Am J Cardiol"},{"key":"2022102603082494300_ehab128-B88","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B89","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","article-title":"Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized dual antiplatelet therapy study","volume":"133","author":"Meredith","year":"2016","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B90","doi-asserted-by":"crossref","first-page":"i5483","DOI":"10.1136\/bmj.i5483","article-title":"Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials","volume":"355","author":"Gargiulo","year":"2016","journal-title":"BMJ"},{"key":"2022102603082494300_ehab128-B91","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B92","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B93","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1055\/s-0039-1679903","article-title":"Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease?","volume":"119","author":"Sumaya","year":"2019","journal-title":"Thromb Haemost"},{"key":"2022102603082494300_ehab128-B94","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B95","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B96","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B97","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.114.013774","article-title":"Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 trial","volume":"131","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B98","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1093\/eurheartj\/ehaa644","article-title":"The long journey of individualizing antiplatelet therapy after acute coronary syndromes","volume":"41","author":"Storey","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B99","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/2047487315599892","article-title":"Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study","volume":"23","author":"Pallisgaard","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2022102603082494300_ehab128-B100","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/STROKEAHA.115.009371","article-title":"Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study","volume":"46","author":"Overvad","year":"2015","journal-title":"Stroke"},{"key":"2022102603082494300_ehab128-B101","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s11606-010-1340-y","article-title":"Diabetes mellitus, glycemic control, and risk of atrial fibrillation","volume":"25","author":"Dublin","year":"2010","journal-title":"J Gen Intern Med"},{"key":"2022102603082494300_ehab128-B102","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","article-title":"Atrial fibrillation and diabetes mellitus: JACC review topic of the week","volume":"74","author":"Wang","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B103","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jamacardio.2016.5224","article-title":"Atrial fibrillation, type 2 diabetes, and non-vitamin K antagonist oral anticoagulants: a review","volume":"2","author":"Plitt","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022102603082494300_ehab128-B104","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/heartjnl-2011-300503","article-title":"Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study","volume":"98","author":"Huxley","year":"2012","journal-title":"Heart"},{"key":"2022102603082494300_ehab128-B105","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/europace\/euv214","article-title":"Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"17","author":"Anselmino","year":"2015","journal-title":"Europace"},{"key":"2022102603082494300_ehab128-B106","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.amjcard.2014.07.045","article-title":"Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)","volume":"114","author":"Fatemi","year":"2014","journal-title":"Am J Cardiol"},{"key":"2022102603082494300_ehab128-B107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12933-014-0123-x","article-title":"Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies","volume":"13","author":"Chang","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2022102603082494300_ehab128-B108","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12872-017-0531-4","article-title":"Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2022102603082494300_ehab128-B109","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-020-01043-2","article-title":"Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants","volume":"19","author":"Chan","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2022102603082494300_ehab128-B111","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B112","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B113","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B114","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American Perspective\u20142018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102603082494300_ehab128-B116","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/europace\/euy110","article-title":"European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS)","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"2022102603082494300_ehab128-B117","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"2022102603082494300_ehab128-B118","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B119","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry","volume":"30","author":"Alberts","year":"2009","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B120","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.118.033898","article-title":"Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B121","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"2022102603082494300_ehab128-B122","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B123","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2008","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B124","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2\u00b0P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B125","doi-asserted-by":"crossref","first-page":"e0135692","DOI":"10.1371\/journal.pone.0135692","article-title":"Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis","volume":"10","author":"Katsanos","year":"2015","journal-title":"PLoS One"},{"key":"2022102603082494300_ehab128-B126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B127","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"2022102603082494300_ehab128-B128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0741-5214(98)70130-2","article-title":"Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure","volume":"28","author":"Sarac","year":"1998","journal-title":"J Vasc Surg"},{"key":"2022102603082494300_ehab128-B130","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B131","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrcardio.2016.111","article-title":"Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease","volume":"13","author":"Capodanno","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2022102603082494300_ehab128-B132","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the early management of acute ischemic stroke: A Guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":". Stroke"},{"key":"2022102603082494300_ehab128-B133","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B134","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B136","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B137","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/CIRCULATIONAHA.118.036656","article-title":"Antithrombotic therapy for stroke prevention","volume":"139","author":"Hankey","year":"2019","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B138","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"2022102603082494300_ehab128-B139","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","article-title":"Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials","volume":"388","author":"Rothwell","year":"2016","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B140","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B141","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B142","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B143","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"Benavente","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B144","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/STROKEAHA.118.024497","article-title":"Antiplatelet therapy after noncardioembolic stroke","volume":"50","author":"Greving","year":"2019","journal-title":"Stroke"},{"key":"2022102603082494300_ehab128-B145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"2022102603082494300_ehab128-B146","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B147","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/CIRCULATIONAHA.113.005451","article-title":"Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry","volume":"129","author":"Oldgren","year":"2014","journal-title":"Circulation"},{"key":"2022102603082494300_ehab128-B148","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B149","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B150","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B151","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B152","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2015.05.141","article-title":"Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial","volume":"196","author":"Brambatti","year":"2015","journal-title":"Int J Cardiol"},{"key":"2022102603082494300_ehab128-B153","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvu024","article-title":"Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial","volume":"1","author":"Ezekowitz","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022102603082494300_ehab128-B154","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2015.07.006","article-title":"Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial","volume":"170","author":"Bansilal","year":"2015","journal-title":"Am Heart J"},{"key":"2022102603082494300_ehab128-B155","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102603082494300_ehab128-B156","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","article-title":"Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study","volume":"46","author":"Paciaroni","year":"2015","journal-title":"Stroke"},{"key":"2022102603082494300_ehab128-B157","doi-asserted-by":"crossref","first-page":"e007034","DOI":"10.1161\/JAHA.117.007034","article-title":"Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study","volume":"6","author":"Paciaroni","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022102603082494300_ehab128-B158","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B159","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1161\/STROKEAHA.118.022856","article-title":"Anticoagulation after stroke in patients with atrial fibrillation","volume":"50","author":"Altavilla","year":"2019","journal-title":"Stroke"},{"key":"2022102603082494300_ehab128-B160","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/eurheartj\/ehy066","article-title":"Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis","volume":"39","author":"Rocca","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102603082494300_ehab128-B161","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.046448","article-title":"Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/23\/2235\/46624825\/ehab128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/23\/2235\/46624825\/ehab128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T03:10:40Z","timestamp":1666753840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/23\/2235\/6186730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":161,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,3,25]]},"published-print":{"date-parts":[[2021,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab128","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,14]]},"published":{"date-parts":[[2021,3,25]]}}}